Jeffrey S Glenn MD PhD

Division of Gastroenterology and Hepatology, Stanford University School of Medicine and Palo Alto Veterans Administration Medical Center, CCSR Building, Room 3115, 269 Campus Drive, Palo Alto, CA 94305-5187, USA

Hepatitis C virus (HCV) is a significant cause of morbidity and mortality, infecting over 150 million people worldwide [1,2]. In spite of recent progress, current therapies remain inadequate for the majority of patients [3-5]. The study of HCV molecular virology is providing an increasing number of new anti-HCV targets. These are being translated into the development of new drugs that offer the prospect of more effective antiviral therapies. This article provides a concise review and update of the major highlights in these efforts.

Was this article helpful?

0 0

Post a comment